ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF N... (t rate of 38% after 8 weeks including pa...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB

Date:8/19/2007

t rate of 38% after 8 weeks, including partial responses and stable disease, for patients with recurrent DIPG in this study represents a unique observation in these end-stage patients and has generated considerable interest.

More than half of the high-grade brain cancers or gliomas over-express epidermal growth factor receptor (EGFR) and for the most advanced brain cancers, glioblastoma multiforme (GBM), the level of expression is even higher. A study involving 29 adults with newly diagnosed high-grade gliomas, including both anaplastic astrocytomas (AA) and GBM, who were treated with surgery, external beam radiotherapy and nimotuzumab showed that the treatment was well tolerated, the median survival time was 17.5 months for the GBM patients, and has not yet been reached for the AA patients.

Nimotuzumab

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). To date nimotuzumab has been administered to approximately 900 patients in more than a dozen clinical trials and on a compassionate basis. It has been approved in several countries and is being provided on a compassionate basis in certain countries including Canada, Germany, Australia and Japan. The drug continues to demonstrate a significantly more benign side-effect profile compared to all the other EGFR-targeting antibodies and small molecules targeting the EGF tyrosine kinase signalling pathway. The absence of any cases of severe rash to date and the very rare instances of any of the other debilitating side effects holds the prospect for nimotuzumab to become best-in-class for this important family of EGFR-targeting agents.

Nimotuzumab global development programs

Nimotuzumab is licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB, S.A., the corporation representing the Centre for Molecular Immunology, which was responsible for the discovery and early development of this unique molecule. Nimotuzumab
'/>"/>

SOURCE YM BioSciences Inc.

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. Jellyfish partners for sales tracking technology
6. GE Healthcare partners with UNC on breast cancer imaging research
7. Manufacturing partnership will move into biotech and biomedical spaces
8. Fergus joins Baird Venture Partners, Caden Bio
9. Avolte Venture Partners reaches capital goal
10. NimbleGen partners with UK biotech firm
11. Big pharma seeks Wisconsin biotech partnerships

Post Your Comments:

(Date:6/18/2013)... 2013 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its preliminary unaudited financial results for the fourth quarter ... 31, 2013. Fourth Quarter of Fiscal ... of fiscal 2013 increased by 33.3% to RMB133.0 million ...

(Date:6/18/2013)... 2013 In support of Swiss contributions ... General of Switzerland in New York is pleased to ... Tûranor PlanetSolar , to Manhattan. PlanetSolar is in ... 2013 tour with scientists on board from the University ... runs exclusively on energy from the sun and eliminates ...

(Date:6/18/2013)... 2013 (PRWEB) June 18, 2013 ... system in North America, has introduced AccountLinx Plus, ... and payroll records between ExakTime’s software and industry-leading ... ExakTime software setup and keeps employee databases up-to-date ... from a business’ current payroll software, directly into ...

(Date:6/18/2013)... 18, 2013 The Regulatory Affairs ... two new offices in Asia—one in Singapore and one ... as RAPS’ Pan-Asia office , serving the Asia ... focused on audiences within China. , The announcement comes ... with five Singapore government agencies to develop and implement ...

[0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City [0] ExakTime Introduces AccountLinx Plus [0] RAPS Opens Offices in Singapore and China

... ORLANDO, Fla. , May 11 GeneLink, Inc. (OTC Bulletin ... quarter ended March 31, 2010 . , , ... , , , ... Quarterly operating loss reduced by 14% over Q4 2009 Comparable quarter gross profit improvement ...

... LONDON , May 11, 2010 The subject ... point in the,scientific community. And as evidence comes to light of the continuing,beneficial ... UK has confirmed what many scientists already believe to,be the case - that ... , , , ...

... , May 11 EnVivo Pharmaceuticals today ... Phase IIb study of its EVP-6124 compound, a selective ... Alzheimer,s disease. The multi-center, dose ranging, placebo controlled, six-month ... is designed to determine the safety and efficacy ...

Cached Biology Technology:GeneLink Reports First Quarter Gains 2 Can Resveratrol Make You Smarter? 2 Can Resveratrol Make You Smarter? 3 Can Resveratrol Make You Smarter? 4 Can Resveratrol Make You Smarter? 5 EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124 2 EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124 3

GeneLink Reports First Quarter Gains Can Resveratrol Make You Smarter?EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124

(Date:6/18/2013)... of Calgary,s Faculty of Medicine have discovered a mechanism ... bacteria. Platelets, a component of blood typically associated with ... and upon detection, seal it off from the rest ... Nature Immunology this week, provide the science ... science community has known that platelets do participate in ...

(Date:6/18/2013)... United Kingdom, the Energy Department,s National Renewable Energy ... recently published a paper describing a novel cellulose-degrading ... quadripunctata , commonly known as the gribble. ... a relatively unique ability to produce their own ... down the biomass they eat. New biomass-degrading enzymes ...

(Date:6/18/2013)... UT Arlington environmental engineer has been awarded a ... to ensure water quality and flow in the ... , Andrew Kruzic, UT Arlington associate professor of ... locations to add monochloramine to the water in ... new pump stations and pipelines. Adding monochloramine is ...

Breaking Biology News(10 mins):Immunity mechanism discovered 2 Novel enzyme from tiny gribble could prove a boon for biofuels research 2 UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2

[0] Immunity mechanism discovered [0] Novel enzyme from tiny gribble could prove a boon for biofuels research [0] UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline

... SAN FRANCISCO, CAOctober 10, 2010Scientists at the Gladstone Institute ... associated with the storage of fat in the liver is ... (HCV). This discovery may offer a new strategy for treating ... throughout the world, and no vaccine is available to prevent ...

... The soils in large areas of the Southern Hemisphere, including ... drying up in the past decade, a group of researchers ... on a global basis. Most climate models have suggested ... land to the atmosphere, would increase with global warming. The ...

... on the way for millions of people on the East ... have reported a key advance in efforts to develop the ... major nuisance to homeowners and a devastating pest to some ... that infects a common weed and found that it shows ...

Cached Biology News:Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells 2 Land 'evapotranspiration' taking unexpected turn: huge parts of world are drying up 2 Land 'evapotranspiration' taking unexpected turn: huge parts of world are drying up 3 Progress toward first commercial repellent for East Coast's stinker 2

Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells Land 'evapotranspiration' taking unexpected turn: huge parts of world are drying up Progress toward first commercial repellent for East Coast's stinker

...

... high PCR specificity *High PCR specificity ... enzyme with unique QIAGEN PCR Buffer ... provided by the stringent built-in hot ... Master Mix and simple reaction setup ...

... (NMPs) make up the internal structural framework of ... as DNA replication, RNA synthesis, and hormone receptor ... to be highly insoluble in vitro , ... soluble nuclear matrix proteins that can be detected ...

Request Info...

Biology Products:

Angiotensin Converting Enzyme Colorimetric Assay Kit from Alpco Diagnostics Hot StarTaq Master Mix Kit from QIAGEN Nuclear Matrix Protein ELISA Kit from Calbiochem T4 DNA Polymerase from Roche Applied Science